Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA Vaccine against the JN.1 Variant

Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, Steven M. Gordon
doi: https://doi.org/10.1101/2024.04.27.24306378

Article Information

doi 
https://doi.org/10.1101/2024.04.27.24306378
History 
  • April 29, 2024.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Nabin K. Shrestha1,*,
  2. Patrick C. Burke2,
  3. Amy S. Nowacki3 and
  4. Steven M. Gordon1,#
  1. 1Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA
  2. 2Infection Prevention, Cleveland Clinic, Cleveland, Ohio, USA
  3. 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA
  1. ↵*Correspondence
    : N. K. Shrestha, 9500 Euclid Avenue / G-21, Cleveland, OH 44195, USA (shrestn{at}ccf.org)
  2. ↵#Alternate corresponding author:
    S. M. Gordon, MD, 9500 Euclid Avenue / G-21, Cleveland, OH 44195, USA (gordons{at}ccf.org)
Back to top
Posted April 29, 2024.
Download PDF
Data/Code
Email
Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA Vaccine against the JN.1 Variant
Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, Steven M. Gordon
medRxiv 2024.04.27.24306378; doi: https://doi.org/10.1101/2024.04.27.24306378
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area